To protect your child, their doctor will give them the pneumococcal conjugate vaccine (PCV). "This is a great example of a ...

US FDA accepts for Priority Review the supplemental Biologics License Application for Merck’s Vaxneuvance™ (pneumococcal 15-valent conjugate vaccine) for use in infants and children. News release.

The 20-valent pneumococcal conjugate vaccine may be preferable due to convenience. Over the last decade, there have been several updates to pneumococcal vaccinations in adolescents and adults, ...

A large surveillance study suggests that an extra pneumococcal vaccine dose for new care home residents can significantly ...

In Texas, the state legislature set laws for vaccine requirements in schools and childcare. The Texas Department of State Health Services (DSHS) creates the rules and works with the Texas Education ...

Merck announces positive topline results from PNEU-DIRECTION (V114-027) and PNEU-PLAN (V114-024) phase 3 pediatric studies for V114, Merck’s Investigational 15-valent pneumococcal conjugate vaccine.

Merck Announces VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Met Key Immunogenicity and Safety Endpoints in Phase 3 Pivotal Trial Evaluating Use in Infants, PNEU-PED (V114-029) ...

The pneumococcal conjugate vaccine (PCV) is the first vaccine proven to be effective in reducing the incidence of invasive pneumococcal disease, pneumonia and acute otitis media in children, and ...

A 10-valent pneumococcal conjugate vaccine, PCV, is effective in reducing the number of new cases of likely-bacterial community-acquired pneumonia in infants in Latin America, according to a study ...

The advisors also voted 14-1 to recommend a pneumococcal conjugate vaccine (PCV) for all PCV-naive adults ages 50 and older. Shortly after the ACIP meeting, CDC Director Mandy Cohen, MD, MPH ...

Among the other recommendations, for those 65 and over who have not gotten a pneumococcal conjugate vaccine or who have unknown vaccination histories, it is recommended that they receive 1 PCV15 ...

To the Editor: In the report by Eskola et al. (Feb. 8 issue)1 of the efficacy of a pneumococcal conjugate vaccine against otitis media, the data argue strongly against their conclusion that “the ...